Post-Hoc Analyses of RADICAVAŽ (edaravone) Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

Thursday, May 2, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Strategic Inclusion Criteria Enabled Detection of Efficacy Intended to be Generalizable to Larger ALS Population



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store